Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% over the past four weeks, the stock looks well positioned for a trend ...
CRBP opened at $6.96 on Monday. Corbus Pharmaceuticals has a one year low of $6.38 and a one year high of $61.90. The stock’s fifty day moving average is $9.32 and its 200-day moving average is ...
Shares of CRBP stock opened at $6.79 on Friday. The stock’s 50 day simple moving average is $9.44 and its 200 day simple moving average is $18.99. Corbus Pharmaceuticals has a twelve month low ...
Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
Hosted on MSN27d
William Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform RecommendationFintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback